Phase II year
2017
(last award dollars: 2018)
Phase II Amount
$1,499,303
Heart disease is the leading cause of mortality and morbidity in the world. Coronary heart disease is the most common type of heart disease and results from the blockage of blood vessels that supply blood to the heart. A heart attack or myocardial infarction (MI) occurs when loss of blood flow causes the death of oxygen- starved cardiomyocytes. In humans, there is little or no significant cardiac muscle regeneration after an injury like a heart attack. Instead, dead cardiomyocytes are replaced by nonfunctional scar tissue, which weakens the heart and can lead ultimately to heart failure and death. Current therapies for heart attack are limited to reducing post-MI heart damage, preventing secondary heart attacks and treating resultant heart failure. Development of therapies that stimulate regeneration of the heart is a strategic priority for the National Heart Lung and Blood Institute. While under intensive study, no such therapies currently exist. MSI-1436 is potent and specific inhibitor of the tyrosine phosphatase PTP1B. PTP1B inactivates diverse receptor tyrosine kinases that regulate innate tissue repair and regeneration processes. Using blinded and randomized experimental and data analysis protocols, we have shown that MSI-1436 stimulates regeneration of adult zebrafish heart, connective, nerve, skin, bone and vascular tissues after amputation, and reverses genetically induced cardiac scar formation. In adult mice, MSI-1436 stimulates stem celI activation in injured skeletal muscle and increases survival, improves heart function ~2-fold, reduces infarct size by 53% and stimulates cellular proliferation 4.5-fold at 4 weeks post-MI. MSI-1436 was previously shown to be well tolerated by patients in Phase 1 and 1b clinical trials as a potential treatment for obesity and type-2 diabetes. The effects of MSI-1436 on regeneration occur at concentrations 50-fold lower than the maximum well tolerated human dose. The demonstrated safety of MSI-1436 and extensive knowledge of its target greatly reduce the time and costs associated with developing this drug as a regenerative medicine therapy for treating acute MI. We will test the efficacy of MSI-1436 in the restoration of heart function in a clinically relevant pig ischemia/reperfusion MI model. Porcine models have become the standard large animal system for studies of cardiac function due to similarities in heart morphology and metabolism to humans. Cardiac function will be measured by echocardiography and infarct size, cardiomyocyte regeneration and cardiomyocyte hypertrophy will be assessed by histology. Testing the efficacy of MSI-1436 in the pig is the required next step towards potential clinical trials. As with all our previous work, proposed pig studies will be blinded and randomized and will be performed in collaboration with lead investigators of the NIH/NHLBI sponsored Consortium for preclinicAl assESsment of cARdioprotective therapies (CAESAR). Demonstrated efficacy in the pig will form an essential component of an FDA IND application for MSI-1436 clinical trials in MI patients.
Public Health Relevance Statement: RELEVANCE Following an injury such as a heart attack, damaged heart cells are replaced with stiff, nonfunctional scar tissue, which reduces heart function and can lead ultimately to heart failure and death. We have identified a drug previously shown to be safe in humans that stimulates recovery of heart function after injury in the adult zebrafish and mouse. Our proposed studies will further test this drug in a pig model of heart attack, the next critical step to eventual tests of the drug in heart attack patients.
Project Terms: Acute; Acute myocardial infarction; Adult; Affect; Amputation; Animal Model; Animals; Applications Grants; Biodistribution; Biological Sciences; Blinded; Blood flow; Blood Vessels; bone; Cardiac; Cardiac Function Study; Cardiac Myocytes; cardiac regeneration; Cardiovascular system; Cause of Death; Cell Proliferation; Cessation of life; Cicatrix; Clinical; Clinical Trials; clinically relevant; Collaborations; Coronary heart disease; cost; Data Analyses; Development; Disease; Dose; Drug Kinetics; Drug or chemical Tissue Distribution; drug testing; Drug vehicle; Echocardiography; efficacy testing; experimental analysis; Family suidae; Goals; Half-Life; Health Care Costs; Heart; heart cell; Heart Diseases; Heart failure; heart function; Heart Injuries; Hemorrhage; Histology; Human; Hypertrophy; improved; Individual; Infarction; inhibitor/antagonist; injured; Injury; innovation; Ischemia; Knowledge; Lead; Measures; Metabolism; Modeling; Morbidity - disease rate; Morphology; mortality; Mus; muscle regeneration; Myocardial Infarction; Myocardial Reperfusion; Myocardium; National Heart, Lung, and Blood Institute; Natural regeneration; Nerve; Non-Insulin-Dependent Diabetes Mellitus; obesity treatment; Oxygen; Patients; Pharmaceutical Preparations; Phase; pre-clinical; prevent; Process; Protein Tyrosine Phosphatase; Protocols documentation; PTPN1 gene; Randomized; Receptor Protein-Tyrosine Kinases; Recovery; Regenerative Medicine; repaired; Reperfusion Injury; Reperfusion Therapy; Research Personnel; restoration; Safety; Skeletal Muscle; Skin; Small Business Innovation Research Grant; small molecule; stem; Stem cells; System; Therapeutic; therapy development; Time; tissue regeneration; tissue repair; Tissues; United States National Institutes of Health; Vascular blood supply; Work; World Health Organization; Zebrafish
